Insider · CIK 0001727794
David Domzalski
Files at YARW (VYNE Therapeutics Inc.). First filing -, latest -.
David Domzalski files SEC Form 4 as CEO, president and director at YARW (VYNE Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; David Domzalski has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| May 29, 2026 | YARW VYNE Therapeutics Inc. | AGrant or award Common Stock | +30,791 | $0.31 | $9,545 | 438,779 | Jun 2, 2026 |
| Mar 31, 2026 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -14,232 | $0.60 | $8,504 | 401,976 | Apr 2, 2026 |
| Dec 31, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -12,684 | $0.58 | $7,358 | 416,208 | Jan 5, 2026 |
| Sep 30, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -12,676 | $0.34 | $4,246 | 428,892 | Oct 2, 2025 |
| Jun 30, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -12,676 | $1.65 | $21k | 441,568 | Jul 2, 2025 |
| Jun 2, 2025 | YARW VYNE Therapeutics Inc. | AGrant or award Common Stock | +8,681 | $0.81 | $7,032 | 454,244 | Jun 3, 2025 |
| Mar 31, 2025 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -30,498 | $1.58 | $48k | 445,563 | Apr 2, 2025 |
| Jan 21, 2025 | YARW VYNE Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +730,000 | $0.00 | $0 | 730,000 | Jan 23, 2025 |
| Dec 31, 2024 | YARW VYNE Therapeutics Inc. | FTax withholding Common Stock | -24,536 | $3.35 | $82k | 476,061 | Jan 2, 2025 |
| Nov 30, 2024 | YARW VYNE Therapeutics Inc. | AGrant or award Common Stock | +3,901 | $2.10 | $8,192 | 500,597 | Dec 3, 2024 |
Questions about David Domzalski
Answered from the filings on this page, as of the latest one.
Is David Domzalski buying or selling?
David Domzalski has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did David Domzalski's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Domzalski has 0.
Where does David Domzalski file Form 4?
David Domzalski has filed Form 4 at YARW (VYNE Therapeutics Inc.) as PRESIDENT AND CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.